GRI Bio, Inc.

NASDAQ: GRI · Healthcare · Biotechnology

PublicHQ La Jolla, CAReports USD

#1143 of 1,394 Healthcare companies by revenuebottom-decile growth

EA Score

——

FH 31DQ —GM —SS 19

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, disclosure history · ↓ revenue growth (YoY), Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$12.0M

Employees

Market cap

$168.0k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02025

Net income-$12.0M-$12.0M2025

Operating income-$12.0M-$12.0M2025

Total assets$8.7M$8.7M2025

Liabilities$2.7M$2.7M2025

Equity$6.0M$6.0M2025

Revenue trend

FY2018 – FY2025 · USD

FY18

FY19

$100.0k

FY20

FY21

FY22

FY23

$22.5M

FY24

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

GRI Bio, Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Health Logic Interactive Inc.——Garrison Film Productions Inc.——Verisante Technology Inc.——BioLife Sciences Inc.——

Key facts

CEOW. Marc Hertz

SectorHealthcare

IndustryBiotechnology

HeadquartersLa Jolla, CA

ExchangeNASDAQ: GRI

Employees4

IPO date2021-02-10

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.